Oestrogen Deprivation Induces Chemokine Production and Immune Cell Recruitment in In Vitro and In Vivo Models of Oestrogen Receptor-Positive Breast Cancer

Scientists investigated the effect of oestrogen deprivation on the expression of chemokines and immune infiltration in vitro and in an ER+ immunocompetent mouse model.
[Breast Cancer Research]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Fluid Flow Exposure Promotes Epithelial-to-Mesenchymal Transition and Adhesion of Breast Cancer Cells to Endothelial Cells

Researchers showed that fluid forces on the order of 1 Pa promoted epithelial-to-mesenchymal transition and adhesion of breast cancer cells to an endothelial monolayer and identified biomarkers were distinctly expressed in patient populations.
[Breast Cancer Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Loss of TRIM31 Promotes Breast Cancer Progression through Regulating K48- and K63-Linked Ubiquitination of p53

The authors showed that TRIM31 was downregulated in breast cancer tissues and negatively correlated with breast cancer progression. Both gain- and loss-of-function assays indicated that TRIM31 inhibited the proliferation, colony formation, migration, and invasion of breast cancer cells.
[Cell Death & Disease]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Downregulation of the FBXO43 Gene Inhibits Tumor Growth in Human Breast Cancer by Limiting Its Interaction with PCNA

Investigators evaluated FBXO43 expression in breast cancer (BC) and analyzed The Cancer Genome Atlas. RT-qPCR and western blotting were utilized to detect FBXO43 expression in BC cell lines.
[Journal of Translational Medicine]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

FAM49B Promotes Breast Cancer Proliferation, Metastasis, and Chemoresistance by Stabilizing ELAVL1 Protein and Regulating Downstream Rab10/TLR4 Pathway

Scientists systematically studied the role of FAM49B in the proliferation, metastasis, apoptosis, and chemoresistance of breast cancer, as well as the corresponding molecular mechanisms and downstream target.
[Cancer Cell International]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

A Careful Reassessment of Anthracycline Use in Curable Breast Cancer

The authors present the problem of overtreatment in early-stage breast cancer, review evidence supporting the use of anthracyclines in the pre-taxane era, analyze comparative trials evaluating taxanes with or without anthracyclines in biologically unselected and selected patient populations.
[npj Breast Cancer]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

ESR1 Mutations and Therapeutic Resistance in Metastatic Breast Cancer: Progress and Remaining Challenges

The authors summarize the pre-clinical characterisation of ESR1 mutations and their association with clinical outcomes in metastatic breast cancer and primary disease.
[British Journal of Cancer]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients

Rhizen Pharmaceuticals AG announced that it has commenced dosing in a Phase II trial to evaluate Tenalisib in patients with locally advanced or metastatic breast cancer.
[Rhizen Pharmaceuticals (BusinessNewsWire, Inc.)]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

Agilent Technologies Inc announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer at high risk of disease recurrence.
[Agilent Technologies, Inc.]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Germline RAD51B Variants Confer Susceptibility to Breast and Ovarian Cancers Deficient in Homologous Recombination

Investigators demonstrated that tumors harboring biallelic RAD51B alteration were deficient in homologous recombination DNA repair deficiency, as evidenced by analysis of sequencing data and in vitro functional assays.
[npj Breast Cancer]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer

Scientists investigated the activity of QBS10072S in vitro with various cell lines including the human TNBC cell line MDA-MB-231 and its brain-tropic derivative MDA-MB-231-BR3, where QBS10072S was found to be preferentially toxic to TNBC cells.
[Molecular Cancer therapeutics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share
Share